Xencor SEC Filings

Xencor reported a sharply wider loss for the quarter ended March 31, 2026 as collaboration revenues fell and investment values declined. Total revenue dropped to $4.5 million from $32.7 million, mainly because prior-year Incyte milestones did not repeat and Ultomiris royalties were reduced.

Net loss attributable to Xencor increased to $128.9 million, or $1.71 per share, from $48.4 million. The company recorded a $51.9 million unrealized loss on its equity stake in Zenas BioPharma and reversed $6.6 million of previously recorded Ultomiris U.S. royalty revenue after Alexion disputed further U.S. payments.

Research and development expenses rose to $64.7 million as Xencor advanced multiple oncology and autoimmune programs, while general and administrative costs were stable. Cash, cash equivalents and marketable debt securities totaled $541.8 million, and management believes this will fund operations into 2028.

Xencor, Inc. reported significantly weaker first-quarter 2026 results. Revenue was $4.5 million, down sharply from $32.7 million a year earlier, reflecting lower collaboration and royalty income and a one-time $6.6 million reduction for disputed Alexion royalties.

The company recorded a net loss attributable to Xencor of $128.9 million, or $(1.71) per share, compared with a $48.4 million loss, or $(0.66) per share, in 2025, driven by higher R&D spending and $50.8 million of other expense from unrealized losses on an equity security. Xencor ended March 31, 2026 with $541.8 million in cash, cash equivalents and marketable debt securities and expects to finish 2026 with $380–$400 million, providing cash runway into mid-2028 while advancing multiple oncology and autoimmune programs.

Xencor, Inc. reported final Phase 1 results for XmAb942, an extended half-life anti‑TL1A antibody for inflammatory bowel disease, and outlined progress across its TL1A portfolio. In healthy participants, XmAb942 was well tolerated, with an estimated terminal half‑life of 74.1 days and no serious or severe adverse events.

Quantitative pharmacology modeling suggests XmAb942 could achieve greater than 99% TL1A inhibition in 86% of patients during 12‑week induction and greater than 90% inhibition in 90% of patients on 12‑weekly maintenance dosing in the ongoing ~220‑patient Phase 2b XENITH‑UC ulcerative colitis study. Xencor also highlighted XmAb412, a TL1A x IL23p19 bispecific using its XenLock format, which showed very high in vitro potency, non‑human primate half‑life over 20 days and is planned to enter a first‑in‑human healthy volunteer study in the third quarter of 2026, with interim XmAb412 data and XENITH‑UC readouts expected through 2027.

Xencor, Inc. is asking stockholders to approve several items at its June 16, 2026 annual meeting, including an amendment to its 2023 Equity Incentive Plan to add 4,000,000 shares, about 5.4% of shares outstanding as of March 31, 2026, designed to cover roughly one year of equity grants. Stockholders will also vote on electing nine directors, ratifying KPMG LLP as auditor for 2026, and an advisory say-on-pay for executives. Xencor ended 2025 with $610.8 million in cash, cash equivalents and marketable securities and highlights multiple oncology and autoimmune programs, including XmAb819 and XmAb541 in solid tumors, TL1A antibodies XmAb942 and XmAb412 in inflammatory bowel disease, and B‑cell–targeted bispecifics plamotamab and XmAb657 in autoimmune diseases.

Xencor, Inc. adopted a new Executive Severance Policy covering its currently serving named executive officers other than the Chief Executive Officer. Eligible executives must sign a participation agreement to receive benefits.

If Xencor terminates an eligible executive without Cause or the executive resigns for Good Reason outside a change in control period and the executive signs a release, the executive is entitled to a lump-sum payment equal to 15 months of base salary plus up to 15 months of paid COBRA health coverage.

If such a termination occurs during a defined change in control period, the executive also receives bonus compensation equal to 15 months of target bonus, a prorated annual bonus, and accelerated vesting of all outstanding, unvested stock options and equity awards, subject to a release of claims.

Xencor Inc senior vice president and CFO Bart Jan Cornelissen reported a sale of 3,499 shares of common stock on April 10, 2026 at an average price of $12.2865 per share. According to the filing, these shares were sold to pay withholding taxes upon the vesting of 14,088 restricted stock units, making this a compensation-related, tax-driven transaction rather than a discretionary open-market sale. After this sale, Cornelissen directly owned 75,898 shares of Xencor common stock.

XNCR notice under Rule 144 reporting the proposed sale of 3,499 shares of Common Stock related to restricted stock vesting on 04/09/2026. The filing also shows 2,517 shares of Common Stock reported sold on 03/05/2026 by Bart Jan Cornelissen.

Xencor, Inc. Schedule 13G shows RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and named managers Peter Kolchinsky and Rajeev Shah report shared beneficial ownership of 4,736,739 shares, representing 6.5% of common stock based on 73,338,642 shares outstanding as of February 17, 2026.

The filing states the Fund directly holds the shares and has delegated voting and dispositive powers to RA Capital; the Reporting Persons disclaim group status and certain beneficial ownership for Section 13(d) purposes.